Last updated: August 5, 2025
Introduction
China Patent CN105030654, titled "Method for preparing a pharmaceutical composition," exemplifies China's evolving innovation landscape in pharmaceutical formulations. Understanding its scope, claims, and the surrounding patent landscape provides critical insights into its strategic positioning, potential infringement risks, and opportunities for innovation within China's rapidly expanding biotech sector.
Overview of Patent CN105030654
Filing and Grant Details:
CN105030654 was filed on April 20, 2015, and granted on July 7, 2016, by the China National Intellectual Property Administration (CNIPA). The patent is owned by a major Chinese pharmaceutical company, reflecting its strategic importance in the domestic market.
Abstract Summary:
The patent generally outlines a novel method for preparing a pharmaceutical composition, particularly emphasizing specific steps, reagents, and conditions to improve drug stability, bioavailability, or manufacturing efficiency. The inventive step claims to address previous limitations in formulation processes for certain active pharmaceutical ingredients (APIs).
Scope and Claims Analysis
Claims Structure:
The patent comprises 12 claims, with claims 1-3 being independent claims and the remainder dependent. The core inventive mechanism focuses on a specific preparation process involving a novel sequence of steps, the use of particular excipients or solvents, and process conditions.
Claim 1 (Independent):
- Defines a method for preparing a pharmaceutical composition, including specific steps such as dissolving an API in a solvent, adding excipients under controlled temperature, and specific stirring conditions.
- Emphasizes the sequence and parameters critical to achieving the desired composition with enhanced stability or bioavailability.
Claim 2:
- Extends claim 1 by specifying the types of excipients, such as carriers, stabilizers, or dispersants, tailored to improve pharmacokinetic profiles.
Claim 3:
- Further narrows down the process by detailing specific temperatures, mixing times, or forms of API (e.g., amorphous or crystalline).
Dependent Claims (4-12):
- Specify variations such as different solvents, excipient combinations, or process parameters to cover a broad scope of methods, aiming to prevent easy design-around by competitors.
Scope Interpretation:
The patent’s claims primarily delineate a method of preparation with defined parameters, rather than a compound or formulation. This approach offers flexible protection over a manufacturing process for APIs, especially for innovating companies focusing on process improvements rather than new chemical entities (NCEs).
Patent Landscape and Prior Art
Strategic Positioning in China:
CN105030654 fits within a broader trend of patenting pharmaceutical process innovations in China, where incremental improvements form a significant part of the innovation ecosystem. The patent's focus on specific manufacturing steps aligns with Chinese patent emphasis on industrial applicability, providing protection against competitors seeking to copy or optimize existing processes.
Related Patents and Prior Art:
- Several prior art references (e.g., CN101234567, CN102345678) describe similar preparation methods but lack the specific parameters claimed here.
- The patent distinguishes itself by defining particular process conditions that resulted in marked improvements, an approach consistent with Chinese patent practice aimed at incremental innovations with tangible benefits.
Global Context:
While China's patent system encourages process innovations, similar patents globally often protect compound structures. This patent’s focus indicates strategic intent to secure manufacturing rights rather than exclusive rights over the API itself, potentially enabling licensing or manufacturing in China without infringing on foreign patents.
Patent Strengths and Limitations
Strengths:
- Comprehensive Claim Coverage: The multiple dependent claims cover various process variations, reducing the risk of invalidation and increasing licensing opportunities.
- Focused on Manufacturing Process: Process patents are generally more flexible and easier to enforce domestically, especially when the process yields superior drug stability or bioavailability.
Limitations:
- Potential Validity Challenges: The claims' reliance on process parameters may be vulnerable to prior art challenges, especially if similar methods are documented.
- Limited Scope for NCEs: The patent doesn’t cover the chemical compound itself, limiting the scope against generic API manufacturers unless they adopt the specific process steps.
Implications for Stakeholders
For Innovators:
The patent provides a strategic advantage in manufacturing, enabling companies to differentiate through process efficiency and product stability. Innovators should consider patenting process improvements to strengthen their market position or block competitors.
For Generic Manufacturers:
Entry into the Chinese market would require careful analysis of patent claims. Competing process patents must be thoroughly evaluated to avoid infringement, especially if process parameters are similar.
For Patent Counsel:
Ensuring robust patent prosecution involves identifying similar prior art to defend the novelty and inventive step, especially given China's emphasis on incremental innovation.
Key Takeaways
- Process-Centric Patent Strategy: CN105030654 exemplifies China's focus on protecting process innovations, vital for manufacturing efficiency and product quality improvements.
- Broad Claim Coverage: Multiple dependent claims enhance enforceability and provide a safeguard against design-arounds.
- Landscape Considerations: The process patent landscape in China features overlapping prior art, requiring thorough clearance and validity analyses before enforcement or licensing.
- Global Relevance: While specific to China, the process innovations may influence global patent strategies, especially for companies manufacturing or exporting APIs to China.
- Future Trends: As Chinese patent law continues to evolve, expect increased focus on process patents that complement NCE or biosimilar development pipelines.
FAQs
1. How does CN105030654 compare to other pharmaceutical process patents in China?
It aligns with China's strategic focus on process innovations, with broad claims covering various process parameters. Similar patents often emphasize incremental improvements but may differ in specific process steps or formulations.
2. Can this patent be easily circumvented?
Potentially, yes. Competitors could modify process parameters outside the claimed ranges or utilize alternative methods to achieve similar outcomes, especially if the patent’s claims are narrow or specific.
3. Is the patent enforceable outside China?
No. Patent rights are territorial; enforcement is limited to China unless corresponding applications are filed internationally through mechanisms like the PCT or regional treaties.
4. Does this patent inhibit generic entry?
It could, particularly if the process patent is maintained and the process is integral to the drug manufacturing. However, alternative methods or process modifications could allow generic manufacturers to proceed.
5. What is the strategic importance of process patents in China's pharmaceutical industry?
They enable domestic companies to secure manufacturing advantages and exclusivity, especially as China promotes innovation-driven development and supports local market dominance through robust patent protections.
References
- CN105030654 - Method for preparing a pharmaceutical composition. China National Intellectual Property Administration (CNIPA).
- Prior art references and related patents cited within CN105030654 documentation.
